Cardiovascular Disease
-
FAME 2 Trial: FFR-Guided PCI vs Medical Therapy in Stable CAD
The FAME 2 trial was a landmark cardiology trial that evaluated whether fractional flow reserve-guided PCI improves outcomes in patients with stable coronary artery disease and functionally significant coronary stenoses. Unlike trials that relied mainly on angiographic stenosis, the FAME 2 trial selected patients based on fractional flow reserve, or FFR. Patients with an FFR
-
FAME Trial: FFR-Guided PCI Versus Angiography-Guided PCI in Multivessel CAD
The FAME trial was a landmark cardiology trial that changed how interventional cardiologists think about coronary stenoses in patients with multivessel coronary artery disease. Instead of relying only on angiographic appearance, the FAME trial tested whether using fractional flow reserve, or FFR, to guide PCI could improve outcomes compared with angiography-guided PCI alone. The main
-
ORBITA Trial: PCI Versus Sham Procedure in Stable Angina
The ORBITA trial was a landmark study in interventional cardiology because it tested whether percutaneous coronary intervention, or PCI, improves symptoms in patients with stable angina when compared with a placebo procedure. Unlike many earlier PCI studies, the ORBITA trial used a double-blind sham-controlled design, making it one of the most rigorous trials ever performed
-
COURAGE Trial: Optimal Medical Therapy With or Without PCI for Stable Coronary Disease
The COURAGE trial was one of the most important landmark cardiology trials because it challenged the routine use of percutaneous coronary intervention, or PCI, in patients with stable coronary artery disease. Before COURAGE, many patients with stable coronary blockages underwent PCI with the expectation that opening the artery would reduce future heart attacks or death.
-
ISCHEMIA Trial: Initial Invasive vs Conservative Strategy in Stable Coronary Disease
The ISCHEMIA trial was one of the most important cardiovascular trials evaluating whether an early invasive strategy improves outcomes in patients with stable coronary artery disease and moderate or severe ischemia. For decades, many clinicians assumed that finding significant ischemia on stress testing meant that patients would benefit from early cardiac catheterization and revascularization. The